Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis

•Patients stable on natalizumab Q4W can switch to Q6W without meaningful efficacy loss.•Ambulation and dexterity outcomes were similar for Q4W and Q6W.•Patients demonstrated improvements in cognitive processing with both Q4W and Q6W.•Similar proportions of patients reported improvements in disability with Q4W or Q6W.•There were no significant differences between Q4W and Q6W for all PROs in NOVA.